Bellevue Life Sciences Acquisition Corp. (BLAC)
NASDAQ: BLAC · Real-Time Price · USD
11.60
-0.06 (-0.51%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
Bellevue Life Sciences Acquisition Corp. does not have significant operations.
It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry.
The company was incorporated in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.
Bellevue Life Sciences Acquisition Corp.
| Country | United States |
| Founded | 2020 |
| IPO Date | Feb 10, 2023 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Kuk Hwang |
Contact Details
Address: 10900 NE 4th Street, Suite 2300 Bellevue, Washington 98004 United States | |
| Phone | 425 635 7700 |
| Website | bellevuespac.com |
Stock Details
| Ticker Symbol | BLAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001840425 |
| CUSIP Number | 079174108 |
| ISIN Number | US0791741087 |
| Employer ID | 84-5052822 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kuk Hyoun Hwang | Chief Executive Officer and Executive Chairman |
| David Jin Yoo | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | S-4/A | Filing |
| Oct 28, 2024 | ARS | Filing |
| Oct 28, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 28, 2024 | 425 | Filing |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 22, 2024 | 8-K | Current Report |
| Oct 18, 2024 | PRE 14A | Other preliminary proxy statements |